![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Eloxatin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607035 |
License data |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Complete |
Elimination half-life | ~10 – 25 minutes[4] |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.150.118 |
Chemical and physical data | |
Formula | C8H14N2O4Pt |
Molar mass | 397.294 g·mol−1 |
3D model (JSmol) | |
| |
![]() ![]() |
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer.[5] It is given by injection into a vein.[5]
Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts.[5][6] Other serious side effects include allergic reactions.[6][5] Use in pregnancy is known to harm the baby.[5] Oxaliplatin is in the platinum-based antineoplastic family of medications.[7] It is believed to work by blocking the duplication of DNA.[5]
Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe.[8] It is on the 2023 World Health Organization's List of Essential Medicines.[9]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search